A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib
Phase of Trial: Phase I/II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs MP 0250 (Primary) ; Osimertinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Molecular Partners AG
- 15 Jun 2018 According to a Molecular Partners AG media release, data from this study will be presented at European Hematology Association (EHA)
- 05 Apr 2018 According to a Molecular Partners AG media release, data from this study will be presented at the American Association of Cancer Research Annual Meeting 2018.
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.